Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07270120 · ClinicalTrials.gov registry record · Phase 1
Senolytics for Secondary Progressive MS
A Phase 1 study, sponsored by Ohio State University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07270120 is a Phase 1 study that has not yet begun recruiting, run by Ohio State University. The registered enrollment target is 30 participants.
The verdict
NCT07270120, a Phase 1 study, has not yet begun recruiting, sponsored by Ohio State University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.
Interventions
- DRUG Dasatinib and quercetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2028-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07270120
The ClinicalTrials.gov registry entry for NCT07270120 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib and quercetin is the first listed.
NCT07270120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07270120 about?
NCT07270120 is a clinical study titled "Senolytics for Secondary Progressive MS". This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a ...
What is the current status of trial NCT07270120?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-01-15. Estimated completion is 2028-01-15.
What interventions are being tested in trial NCT07270120?
The interventions under investigation include: Dasatinib and quercetin (DRUG).
Who is sponsoring clinical trial NCT07270120?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.